Ocata Therapeutics Inc  

(Public, NASDAQ:OCAT)   Watch this stock  
Find more results for OTC:ACTC
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.70
Shares 42.30M
Beta     -
Inst. own 31%

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -4564.66% -22009.72%
Operating margin -8795.92% -22249.30%
EBITD margin - -13499.45%
Return on average assets -46.18% -720.53%
Return on average equity -103.02% -
Employees 37 -
CDP Score - -


33 Locke Dr
MARLBOROUGH, MA 01752-1167
United States - Map
+1-508-7561212 (Phone)
+1-508-2292333 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.